Sneaky Delivery System Revolutionizes Multiple Sclerosis Treatment


Multiple sclerosis, or MS, is an autoimmune disorder in which the immune system attacks myelin surrounding nerves. It is a debilitating disease with no cure. Luckily, as our understanding of triggers in the immune system deepens, so does the likelihood of developing more effective treatments or even a cure. A new study shows just how far we have come.

A team of scientists from Northwestern University, University Hospital Zurich in Switzerland, and University Medical Center Hamburg-Eppendorf in Germany demonstrated that resetting a patient's immune system was safe and reduced the targeting of myelin by 50%-75%. The phase 1 trial supported moving into a phase 2 trial in Switzerland after funds are raised. It is great news for patients and will likely revolutionize the way we treat autoimmune diseases and allergy medications. However, it will be a long time before it readily competes with Gilenya from Novartis . Fool contributor Maxx Chatsko breaks it down for investors in the following video.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Sneaky Delivery System Revolutionizes Multiple Sclerosis Treatment originally appeared on

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published